Vol 19, No 2 (2016)

Date published: 2016-07-29

Table of Contents

open access

paid access

Editorial

Editorial

Renata Mikołajczak, Grzegorz Kamiński

DOI: 10.5603/NMR.2016.0014
Nucl. Med. Rev 2016;19(2):65.
Original articles

99mTc-EDDA/HYNIC-TOC in the diagnosis of differentiated thyroid carcinoma refractory to radioiodine treatment

Rafał Czepczyński, Maria Gryczyńska, Marek Ruchała

DOI: 10.5603/NMR.2016.0015
Pubmed: 27479883
Nucl. Med. Rev 2016;19(2):67-73.

99mTc-EDDA/HYNIC-TOC in management of patients with head and neck somatostatin receptor positive tumors

Mate Trogrlic, Stanko Tezak

DOI: 10.5603/NMR.2016.0016
Pubmed: 27479884
Nucl. Med. Rev 2016;19(2):74-80.

Clinical application of SPECT-CT with 99mTc-Tektrotyd in bronchial and thymic neuroendocrine tumors (NETs)

Sonya Sergieva, Bozhil Robev, Milena Dimcheva, Albena Fakirova, Radka Hristoskova

DOI: 10.5603/NMR.2016.0017
Pubmed: 27479885
Nucl. Med. Rev 2016;19(2):81-87.

Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT

Dorota Madrzak, Renata Mikołajczak, Grzegorz Kamiński

DOI: 10.5603/NMR.2016.0018
Pubmed: 27479886
Nucl. Med. Rev 2016;19(2):88-92.

Limitations and pitfalls of 99mTc-EDDA/HYNIC-TOC (Tektrotyd) scintigraphy

Ildikó Garai, Sandor Barna, Gabor Nagy, Attila Forgacs

DOI: 10.5603/NMR.2016.0019
Pubmed: 27479887
Nucl. Med. Rev 2016;19(2):93-98.

Evaluation of neuroendocrine tumors with 99mTc-EDDA/HYNIC TOC

Vera Artiko, Aida Afgan, Jelena Petrović, Branislava Radović, Nebojša Petrović, Marina Vlajković, Dragana Šobić-Šaranović, Vladimir Obradović

DOI: 10.5603/NMR.2016.0020
Pubmed: 27479786
Nucl. Med. Rev 2016;19(2):99-103.

Oxidation of methionine — is it limiting the diagnostic properties of 99mTc-labeled Exendin-4, a Glucagon-Like Peptide-1 receptor agonist?

Barbara Janota, Urszula Karczmarczyk, Ewa Laszuk, Piotr Garnuszek, Renata Mikołajczak

DOI: 10.5603/NMR.2016.0021
Pubmed: 27479787
Nucl. Med. Rev 2016;19(2):104-110.
Reviews

Neuroendocrine neoplasms and somatostatin receptor subtypes expression

Jerzy Hankus, Romana Tomaszewska

DOI: 10.5603/NMR.2016.0022
Pubmed: 27479788
Nucl. Med. Rev 2016;19(2):111-117.

NEN — the role of somatostatin receptor scintigraphy in clinical setting

Marta Opalińska, Alicja Hubalewska-Dydejczyk, Anna Sowa-Staszczak, Agnieszka Stefańska

DOI: 10.5603/NMR.2016.0023
Pubmed: 27479789
Nucl. Med. Rev 2016;19(2):118-125.

Radiopharmaceuticals for somatostatin receptor imaging

Renata Mikołajczak, Helmut R. Maecke

DOI: 10.5603/NMR.2016.0024
Pubmed: 27479790
Nucl. Med. Rev 2016;19(2):126-132.
Future events

Calendar of Events 2016

Agnieszka Krajewska

DOI: 10.5603/MR.2016.0025
Nucl. Med. Rev 2016;19(2):133.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl